文献速递造血干细胞移植与细胞治疗MDS 与骨髓增殖性肿瘤

2024年异基因造血干细胞移植治疗骨髓纤维化更新:当前数据及风险分层与管理应用综述

2024 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management.
PubMed 文献 · Am J Hematol · 2024-03-07

异基因造血干细胞移植仍是骨髓纤维化唯一治愈手段,移植相关死亡与复发是两大并发症。本文综述患者选择、预后系统、脾大管理、预处理方案、移植物抗宿主病预防、复发监测与治疗等方面的新进展。

要点

  • 异基因造血干细胞移植仍是骨髓纤维化唯一治愈手段。
  • 移植相关死亡与复发仍是需要解决的两大并发症。
  • 综述涵盖患者选择、预后系统、脾大管理、预处理、移植物抗宿主病预防及复发治疗等更新。

核心结论

  • 综述概述了目前可用于骨髓纤维化患者的新移植平台,以及持续存在的问题,包括高龄合并骨髓纤维化和炎症性疾病。
  • 复发还需要对驱动突变进行积极监测,并早期应用细胞治疗。

研究设计与样本

  • 综述类文章,通过已发表论文分析异基因造血干细胞移植的不同方面。

主要发现

  • 提供了关于患者选择、预后系统、脾大管理、预处理方案、移植结局预测、干细胞来源、干细胞供者、移植物抗宿主病预防、急变期患者、造血重建、疾病标志物、供者嵌合状态及复发治疗等方面的变化与更新。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Allogeneic hemopoietic stem cell transplantation (HSCT) currently remains the only curative treatment for patients with myelofibrosis (MF). Transplant related mortality (TRM) and relapse, remain two significant complications which need to be addressed. AIMS: The aim of this manuscript is to review current available reports on changes which have recently occurred, to improve the outcome of MF patients undergoing an allogeneic HSCT. METHODS: Published papers were used to analyze different aspects of allogeneic HSCT. RESULTS: Changes and updates are provided on selection of patients, prognostic systems, managing splenomegaly, conditioning regimens, predicting transplant outcome, stem cell sources, stem cell donors, graft versus host disease (GvHD) prophylaxis, patients with blast phase, hematopoietic reconstitution, disease markers, donor chimerism, and treatment of relapse. CONCLUSIONS: The review outlines new transplant platforms which are now available for patients with myelofibrosis, together with persisting problems, among which, older age combined with marrow fibrosis and an inflammatory disease. Relapse also requires aggressive monitoring of drivers mutations, and early cellular therapy.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Ali H, Bacigalupo A. 2024 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management. Am J Hematol. 2024. PMID: 38450790. doi:10.1002/ajh.27274

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。